Search research articles
Contact Us
Filters
Showing results (961-970 of 1,023) with videos related to
Page
of 103
Sort By:
Journal of the American College of Radiology : JACR
|
July 11, 2021
Managing Incidental Findings on Thoracic CT: Lung Findings. A White Paper of the ACR Incidental Findings Committee
Reginald F Munden, William C Black, Thomas E Hartman, et al.
JCO Precision Oncology
|
August 11, 2021
Clinical Outcomes in Non-Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling
Hai T Tran, Vincent K Lam, Yasir Y Elamin, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 26, 2025
Drug Development
Kathryn A Haynes, Zackery A Cope, Sean-Paul Gerard Williams, et al.
Journal for Immunotherapy of Cancer
|
September 6, 2019
Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy
Hari Menon, Dawei Chen, Rishab Ramapriyan, et al.
Journal of the American College of Radiology : JACR
|
June 27, 2018
Managing Incidental Findings on Thoracic CT: Mediastinal and Cardiovascular Findings. A White Paper of the ACR Incidental Findings Committee
Reginald F Munden, Brett W Carter, Caroline Chiles, et al.
Plos One
|
February 15, 2024
Characterization of covalent inhibitors that disrupt the interaction between the tandem SH2 domains of SYK and FCER1G phospho-ITAM
Frances M Bashore, Vittorio L Katis, Yuhong Du, et al.
Biorxiv : the Preprint Server for Biology
|
August 7, 2023
Characterization of covalent inhibitors that disrupt the interaction between the tandem SH2 domains of SYK and FCER1G phospho-ITAM
Frances M Bashore, Vittorio L Katis, Yuhong Du, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 23, 2019
Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression
E J Aguilar, B Ricciuti, J F Gainor, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 28, 2005
Rapamycin analogs with reduced systemic exposure
Rolf Wagner, Karl W Mollison, Luping Liu, et al.
Physics in Medicine and Biology
|
May 21, 2016
Characterizing proton-activated materials to develop PET-mediated proton range verification markers
Jongmin Cho, Geoffrey S Ibbott, Matthew D Kerr, et al.
Page
of 103
Search research articles
Search
Showing results (961-970 of 1,023) with videos related to
Sort By:
Page
of 103
Journal of the American College of Radiology : JACR
|
July 11, 2021
Managing Incidental Findings on Thoracic CT: Lung Findings. A White Paper of the ACR Incidental Findings Committee
Reginald F Munden, William C Black, Thomas E Hartman, et al.
JCO Precision Oncology
|
August 11, 2021
Clinical Outcomes in Non-Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling
Hai T Tran, Vincent K Lam, Yasir Y Elamin, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 26, 2025
Drug Development
Kathryn A Haynes, Zackery A Cope, Sean-Paul Gerard Williams, et al.
Journal for Immunotherapy of Cancer
|
September 6, 2019
Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy
Hari Menon, Dawei Chen, Rishab Ramapriyan, et al.
Journal of the American College of Radiology : JACR
|
June 27, 2018
Managing Incidental Findings on Thoracic CT: Mediastinal and Cardiovascular Findings. A White Paper of the ACR Incidental Findings Committee
Reginald F Munden, Brett W Carter, Caroline Chiles, et al.
Plos One
|
February 15, 2024
Characterization of covalent inhibitors that disrupt the interaction between the tandem SH2 domains of SYK and FCER1G phospho-ITAM
Frances M Bashore, Vittorio L Katis, Yuhong Du, et al.
Biorxiv : the Preprint Server for Biology
|
August 7, 2023
Characterization of covalent inhibitors that disrupt the interaction between the tandem SH2 domains of SYK and FCER1G phospho-ITAM
Frances M Bashore, Vittorio L Katis, Yuhong Du, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 23, 2019
Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression
E J Aguilar, B Ricciuti, J F Gainor, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 28, 2005
Rapamycin analogs with reduced systemic exposure
Rolf Wagner, Karl W Mollison, Luping Liu, et al.
Physics in Medicine and Biology
|
May 21, 2016
Characterizing proton-activated materials to develop PET-mediated proton range verification markers
Jongmin Cho, Geoffrey S Ibbott, Matthew D Kerr, et al.
Page
of 103